Danske Bank A S Makes New $367.47 Million Investment in Johnson & Johnson $JNJ

Key Points

• Danske Bank A/S bought 1,981,807 shares of Johnson & Johnson in Q3 — a new stake valued at about $367.47 million that represents roughly 0.9% of Danske’s portfolio and makes J&J its 14th‑largest holding (Danske owns ~0.08% of JNJ).
• Analyst sentiment is broadly positive with multiple buy/outperform ratings and raised targets (HSBC recently lifted its target to $280); J&J’s consensus rating is a Moderate Buy with a consensus target around $236.57.
• Company catalysts include clinical progress (a Phase I win for a bladder cancer therapy) and a regulatory filing for TECVAYLI in multiple myeloma, though the stock recently slid about 2.1% amid short‑term profit‑taking.

Danske Bank A S bought a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,981,807 shares of the company's stock, valued at approximately $367,467,000. Johnson & Johnson comprises approximately 0.9% of Danske Bank A S's investment portfolio, making the stock its 14th biggest holding. Danske Bank A S owned approximately 0.08% of Johnson & Johnson as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson during the 3rd quarter worth $26,000. Clayton Financial Group LLC bought a new stake in Johnson & Johnson in the third quarter valued at $28,000. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson during the second quarter valued at $27,000. Semmax Financial Advisors Inc. grew its position in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after acquiring an additional 72 shares during the last quarter. Finally, Turning Point Benefit Group Inc. bought a new position in shares of Johnson & Johnson during the third quarter worth about $41,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: HSBC raised its price target on JNJ to $280 and upgraded to a "buy," calling for meaningful upside versus current levels — a fresh, high‑profile endorsement that supports longer‑term bullishness. Article Title
• Positive Sentiment: Independent analyst pieces highlight a $280 target and argue JNJ’s recent outperformance (strong YTD and 1‑yr gains) is backed by pipeline and portfolio strength — reinforcing the narrative of further upside for investors who can wait. Why One Analyst Thinks Johnson & Johnson Reaches $280
• Positive Sentiment: JNJ reported a phase I win for its bladder cancer therapy (Erda‑iDRS) with strong responses and manageable safety — clinical progress that could support future revenue if later‑stage trials succeed. JNJ's Bladder Cancer Therapy Meets Key Goal
• Positive Sentiment: Regulatory progress for TECVAYLI (teclistamab) — J&J submitted a Type II variation to the EMA seeking approval in relapsed/refractory multiple myeloma — an important potential mid‑term revenue catalyst if approved. TECVAYLI Opportunity
• Neutral Sentiment: Johnson & Johnson launched pulsed field ablation tech in Peru — incremental product expansion in med‑tech markets, supportive but unlikely to meaningfully shift near‑term revenue. PFA Peru Launch
• Neutral Sentiment: Industry news (e.g., Monte Rosa supply agreement) and market commentary reassessing JNJ’s valuation after large multi‑year gains — useful context for positioning but not company‑specific catalysts. Monte Rosa Agreement
• Negative Sentiment: Shares slid today even as the broader market rose — coverage notes the drop reflects short‑term profit‑taking and rotation after a strong run, as well as lighter-than-average volume. That intraday weakness outweighed the new buy rating and clinical headlines. JNJ Stock Slides

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. UBS Group reiterated a "buy" rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Wolfe Research raised their price target on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an "outperform" rating in a research note on Monday, January 5th. Scotiabank reaffirmed an "outperform" rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Royal Bank Of Canada increased their price objective on Johnson & Johnson from $240.00 to $255.00 and gave the stock an "outperform" rating in a report on Tuesday, February 3rd. Finally, Freedom Capital cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $236.57.

Johnson & Johnson Stock Down 2.1%

Johnson & Johnson stock opened at $238.18 on Wednesday. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $251.71. The stock has a market cap of $573.68 billion, a price-to-earnings ratio of 21.55, a PEG ratio of 2.40 and a beta of 0.34. The company's 50-day moving average price is $233.35 and its two-hundred day moving average price is $207.56. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson's dividend payout ratio (DPR) is presently 47.06%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.